Cardiovascular Research

First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperf

Authors: Robert A Kloner|||Joan S Dow|||Anil Bhandari

Affiliations: + Expand

Abstract

There are few safe antiarrhythmics for ischemic heart disease. Whereas ranolazine is a promising late INa blocker with antiarrhythmic effects, and devoid of pro-arrhythmic properties, there are no direct comparisons between ranolazine and other antiarrhythmic agents in an ischemia/reperfusion setting. HYPOTHESIS AND METHODS: To determine whether ranolazine was as effective as sotalol and lidocaine to reduce ischemia/reperfusion-induced arrhythmias, anesthetized rats were subjected to 5 minutes of proximal left coronary artery occlusion plus 5 minutes of reperfusion, which causes severe ventricular arrhythmias. At 21 minutes prior to coronary occlusion, rats (n = 20 per group) were randomized to receive either sotalol (intravenous [IV] bolus 5 mg/kg, 10 mg/kg per hour infusion), lidocaine (IV bolus 2.5 mg/kg, 2.5 mg/kg/hr infusion), ranolazine (IV bolus 3.3 mg/kg, 3.2 mg/kg per hour infusion), or saline (control).

---

Chemical List

Acetanilides|||Anti-Arrhythmia Agents|||Enzyme Inhibitors|||Piperazines|||Lidocaine|||Sotalol|||Ranolazine